Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Angion logo — Angion is committed to transforming the treatment paradigm f...

Angion

Angion is committed to transforming the treatment paradigm for patients suffering from fibrotic diseases.

Founded 1998 United States United States 19 employees Post-IPO Equity Total: $84.27M Biopharma, Biotechnology

General Information

Company Name Angion
Founded Year 1998
Location United States United States
Employees 19
Industries Biopharma, Biotechnology
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Angion. To contact Angion, visit angion.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Angion compare?

A PDF of Angion and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Angion soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Angion

Angion is a late-stage biopharmaceutical company committed to transforming the treatment paradigm for patients suffering from fibrotic diseases. Established in 1998 and headquartered in the United States, Angion focuses on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Their goal is to revolutionize the treatment paradigm for patients facing potentially life-threatening conditions with no approved medicines or with limitations in existing approved medicines. In a recent funding round on 05 February 2021, Angion secured a $25.00M post-IPO equity investment, with Vifor Pharma as the investor. This investment signifies both the potential of Angion's innovative approach and the confidence of established players in the biopharmaceutical industry in the company's future endeavors. With its clear focus and significant strides in addressing critical unmet medical needs, Angion presents a promising opportunity for investors looking to support groundbreaking advancements in the treatment of fibrotic diseases.

Taxonomy: biopharmaceutical company, drug discovery, organ restoration, renal disease, fibrotic diseases, acute organ injuries, small molecule therapeutics, clinical-stage, delayed graft function, acute kidney injury, cardiopulmonary bypass, phase 3, phase 2, late-stage, patient treatment paradigm

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $25.00M 1
Vifor Pharma
05 Feb 2021
Venture Round Undisclosed 1
Formic Ventures
Formic Ventures
23 Jun 2020
Grant $4.76M 1
U.S. Department of Defense
03 Apr 2019
Venture Round $35.00M -
04 Jan 2019
Venture Round $15.00M -
17 Jul 2018
Venture Round $4.36M -
20 Feb 2015
Grant $149.76K 1
National Science Foundation
National Science Foundation
11 Dec 2013

Angion Alternatives & Competitors

View All Alternatives
Angion vs
Molecure
Molecure Poland

Fate can be altered.

Post-IPO Secondary
85 employees
Biopharma, Biotechnology
Angion vs
Kinarus Therapeutics
Kinarus Therapeutics Switzerland

Kinarus Therapeutics is a clinical-stage company developing therapies for viral, respiratory and ocu...

Post-IPO Equity
5 employees
Biopharma, Biotechnology
Angion vs
Promedior
Promedior

Pioneering advanced therapies to heal fibrotic and inflammatory diseases at their source, enhancing...

Venture round
Biopharma, Biotechnology
View all alternatives

FAQ About Angion

Angion is committed to transforming the treatment paradigm for patients suffering from fibrotic diseases.
Angion was founded in 1998.
Angion is headquartered in United States.
Angion operates in Biopharma and Biotechnology. Its work centres on biopharmaceutical company, drug discovery, organ restoration and renal disease.
Angion has approximately 19 employees.
Angion has completed 7 funding rounds, raising a total of $84.27M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Angion include Molecure, Kinarus Therapeutics, Promedior, Pathalys Pharma, DiaMedica Therapeutics Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Angion and Molecure are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Angion, https://bouncewatch.com/company/angion, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes